human
respiratori
syncyti
viru
rsv
infect
children
age
two
reinfect
occur
sporad
throughout
life
young
children
elderli
especi
risk
sever
lower
respiratori
tract
infect
result
extens
morbid
million
hospit
per
year
develop
rsv
vaccin
thu
prioriti
date
potent
rsvneutral
antibodi
recogn
rsv
fusion
f
surfac
glycoprotein
rsv
f
type
fusion
glycoprotein
compris
precursor
activ
furin
cleavag
form
prefus
pref
trimer
disulfidelink
heterodim
pref
conform
rsv
f
undergo
substanti
structur
rearrang
transit
postfus
conform
part
essenti
role
merg
viral
host
cell
membran
entri
among
sever
antigen
site
rsv
f
associ
neutral
activ
antigen
site
locat
membran
distal
end
pref
head
region
recogn
sever
potent
rsvneutral
antibodi
thu
far
identifi
major
target
neutral
antibodi
elicit
rsvinfect
human
antigen
site
present
pref
conform
rsv
f
recombin
pref
spontan
rearrang
postfus
conform
sever
variant
rsv
f
stabil
pref
form
creat
use
immunogen
sctm
scdm
preserv
antigen
site
shown
elicit
high
titer
neutral
antibodi
mice
cotton
rat
macaqu
howev
antigen
site
compris
less
surfac
area
rsv
f
trimer
glycoprotein
provid
ampl
opportun
antigen
competit
irrelev
less
neutralizationsensit
epitop
rsv
f
vaccin
specif
present
antigen
site
might
thu
potenti
focu
improv
qualiti
antibodi
respons
immunefocus
vaccin
respons
remov
extran
epitop
vaccin
immunogen
observ
elicit
target
antibodi
respons
sever
studi
rsv
incorpor
two
rsv
f
helic
antigen
site
ii
protein
scaffold
result
immunogen
could
elicit
bind
antibodi
site
ii
mice
addit
interven
antibodi
site
ii
macaqu
though
macaqu
titer
appear
much
lower
elicit
trimer
immunogen
rsv
f
trimer
influenza
viru
headless
stalkonli
immunogen
hemagglutinin
ha
glycoprotein
induc
significantli
higher
titer
protect
ha
stemdirect
antibodi
season
influenza
trival
inactiv
vaccin
mice
ferret
ha
stemdirect
antibodi
reduc
symptom
diseas
macaqu
furthermor
middl
east
respiratori
syndrom
coronaviru
mice
immun
receptorbind
domain
rbd
contain
subunit
elicit
rbdreactiv
neutral
antibodi
mice
immun
dna
fulllength
spike
protein
therefor
hypothes
headonli
immunogen
might
abli
boost
antigen
site
respons
complet
f
glycoprotein
test
hypothesi
design
seri
rsv
f
immunogen
compris
membranedist
half
head
region
rsv
f
glycoprotein
antigen
site
intact
membraneproxim
half
stalk
region
complet
remov
four
headonli
rsv
f
immunogen
evalu
primeboost
mous
immunogen
studi
two
boost
rsvneutral
titer
level
compar
boost
rsv
f
trimer
although
increas
site
antibodi
amino
acid
sequenc
rsv
f
subtyp
strain
mutat
use
start
point
design
design
includ
histag
streptag
use
purif
antibodybind
assay
headonli
rsv
f
variant
express
transient
transfect
cell
thermo
fisher
scientif
use
thermo
fisher
scientif
cultur
supernat
harvest
day
post
transfect
centrifug
remov
cell
debri
supernat
sterilefilt
head
rsv
f
variant
purifi
nickel
streptactin
iba
mo
affin
chromatographi
follow
sizeexclus
chromatographi
sec
use
superdex
column
ge
healthcar
pa
purif
tag
remov
rsv
f
protein
digest
u
restrictiongrad
biotinyl
thrombin
novagen
wi
per
mg
immunogen
overnight
room
temperatur
cleav
immunogen
subsequ
pass
streptavidin
column
ge
healthcar
pa
captur
thrombin
purifi
second
round
sec
phosphatebuff
salin
pb
prior
analysi
immun
molecular
weight
protein
elut
sec
estim
fit
elut
volum
regress
line
plot
log
molecular
weight
versu
vevo
vtvo
sever
standard
protein
elut
volum
vo
void
volum
column
vt
total
volum
column
antibodi
express
transient
cotransfect
hek
cell
thermo
fisher
scientif
heavi
lightchain
plasmid
use
thermo
fisher
scientif
cell
supernat
harvest
day
pass
protein
agaros
ge
healthcar
pa
bound
antibodi
wash
pb
elut
igg
elut
buffer
pierc
il
volum
trishcl
ph
fab
creat
digest
igg
lysc
proteas
cleav
fc
region
remov
pass
mixtur
protein
agaros
fab
purifi
sec
construct
assess
use
micropl
format
high
throughput
express
follow
elisabas
antigen
evalu
describ
previous
briefli
h
prior
transfect
hek
cell
thermo
fisher
scientif
seed
well
micropl
densiti
cellsml
express
medium
high
glucos
dmem
supplement
ultralow
igg
fetal
bovin
serum
amino
acid
incub
h
plasmid
dna
truefectmax
unit
biosystem
md
mix
ad
grow
cell
plate
incub
one
day
post
transfect
enrich
medium
high
glucos
dmem
plu
ultralow
igg
fetal
bovin
serum
nonessenti
amino
acid
glutamin
ad
well
plate
return
incub
continu
cultur
day
five
post
transfect
supernat
express
rsv
f
variant
harvest
test
elisa
bind
motavizumab
antibodi
use
micropl
incub
harvest
supernat
one
week
two
week
five
week
elisa
repeat
recognit
antibodi
respect
octet
instrument
pall
fortebio
llc
ca
use
measur
bind
kinet
rsv
f
headonli
variant
antigen
site
site
iitarget
motavizumab
antibodi
assay
perform
agit
set
rpm
pb
supplement
bovin
serum
albumin
bsa
order
minim
nonspecif
interact
final
volum
solut
assay
perform
tilt
black
plate
greiner
bioon
nc
rsv
f
headonli
variant
pb
buffer
use
load
antihistag
probe
typic
captur
level
load
step
nm
variabl
within
row
eight
tip
exceed
nm
step
nm
unit
measur
chang
interfer
pattern
white
light
reflect
surfac
biosensor
tip
compar
intern
refer
measur
realtim
correl
chang
number
bound
molecul
biosensor
tip
surfac
also
defin
chang
respons
unit
measur
nm
biosensor
tip
equilibr
pb
bsa
prior
measur
associ
antigen
bind
fragment
fab
solut
fab
allow
dissoci
parallel
correct
subtract
systemat
baselin
drift
carri
subtract
measur
record
load
sensor
incub
pb
bsa
data
analysi
curv
fit
carri
use
octet
analysi
softwar
version
pall
fortebio
llc
ca
experiment
data
fit
bind
equat
describ
interact
global
analys
complet
data
set
assum
revers
bind
full
dissoci
carri
use
nonlinear
leastsquar
fit
allow
singl
set
bind
paramet
obtain
simultan
concentr
measur
singl
experi
assess
physic
stabil
prefus
conform
rsv
f
head
region
protein
variou
stress
condit
treat
protein
varieti
pharmaceut
relev
stress
extrem
ph
high
temperatur
low
high
osmolar
repeat
freezethaw
cycl
physic
stabil
treat
rsv
f
headonli
protein
evalu
retent
bind
antigenbind
fragment
fab
site
antibodi
treatment
carri
protein
concentr
ph
treatment
rsv
f
glycoprotein
solut
adjust
either
ph
citrat
buffer
ph
acid
cap
buffer
incub
room
temperatur
minut
subsequ
neutral
ph
tri
buffer
temperatur
treatment
carri
incub
rsv
f
glycoprotein
solut
minut
pcr
cycler
heat
lid
osmolar
treatment
rsv
f
glycoprotein
solut
origin
contain
mm
nacl
either
dilut
mm
tri
buffer
ph
osmolar
mm
nacl
adjust
final
concentr
protein
solut
incub
minut
room
temperatur
return
mm
salt
ad
nacl
dilut
mm
tri
buffer
respect
concentr
freezethaw
treatment
carri
repeatedli
freez
rsv
f
glycoprotein
solut
liquid
nitrogen
thaw
ten
time
rsv
f
glycoprotein
dilut
pb
bsa
reduc
nonspecif
bind
abil
bind
fab
measur
octet
instrument
use
protocol
describ
assay
perform
tilt
black
plate
greiner
bioon
nc
agit
set
rpm
well
volum
trimer
dimer
rsv
f
head
protein
immobil
use
antistreptag
igg
due
reduc
avid
interact
antistreptag
antibodi
monomer
rsv
f
head
protein
immobil
use
higher
affin
antigen
site
iidirect
motavizumab
igg
preimmobil
antimous
fc
biosensor
tip
load
antistreptag
pb
bsa
preimmobil
antihuman
fc
biosensor
tip
load
motavizumab
igg
pb
bsa
variabl
load
within
row
eight
tip
exceed
nm
step
biosensor
tip
equilibr
pb
bsa
prior
load
rsv
f
variant
biosensor
tip
equilibr
pb
bsa
prior
measur
associ
fab
pb
bsa
fab
allow
dissoci
pb
bsa
parallel
correct
subtract
systemat
baselin
drift
carri
subtract
measur
record
load
sensor
incub
pb
bsa
trimer
rsv
f
head
protein
well
monomer
rsv
f
head
protein
physic
stabil
report
ratio
steadi
state
level
stress
treatment
due
reduc
avid
interact
antistreptag
antibodi
dimer
rsv
f
head
protein
dissoci
antigen
biosensor
observ
second
equilibr
bind
account
physic
stabil
report
ratio
maximum
level
stress
treatment
sampl
dilut
buffer
contain
mm
hepe
ph
mm
nacl
adsorb
freshli
glowdischarg
carbonfilm
grid
wash
buffer
stain
uranyl
format
imag
collect
magnif
semiautomat
use
serialem
fei
tecnai
microscop
oper
kv
equip
x
eagl
ccd
camera
pixel
size
nmpx
particl
pick
manual
use
swarm
mode
softwar
packag
dataset
complex
motavizumab
complex
motavizumab
complex
complex
motavizumab
complex
motavizumab
complex
contain
particl
respect
dataset
complex
motavizumab
complex
motavizumab
complex
complex
motavizumab
complex
motavizumab
complex
contain
particl
respect
initi
referencefre
classif
perform
use
case
qualiti
class
insuffici
classif
repeat
use
referencefre
rotat
align
classif
ap
c
referencefre
align
correspond
analysi
spider
anim
experi
review
approv
anim
care
use
committe
vaccin
research
center
niaid
nih
anim
protocol
identif
number
anim
hous
care
accord
local
state
feder
institut
polici
american
associ
accredit
laboratori
anim
care
aaalac
accredit
facil
nih
prior
experi
femal
hybrid
mice
first
filial
offspr
cross
balbcj
femal
c
male
jackson
laboratori
known
age
week
week
intramuscularli
inject
rsv
f
immunogen
week
zero
week
three
homolog
primeboost
week
final
boost
four
group
n
mice
initi
prime
headonli
immunogen
three
group
n
prime
frozen
rsv
f
variant
immunogen
protein
thaw
ice
mix
ww
polyinosin
polycytidyl
acid
poli
c
invivogen
ca
adjuv
ie
immunogen
poli
c
per
anim
immun
inject
take
place
within
one
hour
immunogen
adjuv
prepar
two
inject
site
use
immun
advers
effect
immun
observ
blood
collect
least
three
day
immun
week
two
week
five
week
seven
week
post
initi
immun
viral
stock
prepar
maintain
previous
describ
recombin
mkatersv
express
prototyp
subtyp
strain
f
gene
katushka
fluoresc
protein
construct
report
hotard
et
al
cell
atcc
va
maintain
eagl
minim
essenti
medium
contain
fetal
bovin
serum
emem
supplement
glutamin
penicillin
streptomycin
neutral
titer
measur
fluoresc
plate
reader
neutral
assay
describ
previous
briefli
x
cell
seed
black
optic
bottom
plate
nunc
plate
thermo
fisher
scientif
sera
sampl
assay
fourfold
dilut
mix
equal
volum
recombin
mkatersv
express
prototyp
f
gene
subtyp
strain
katushka
fluoresc
protein
incub
one
hour
next
dilut
sampl
viru
ad
cell
assay
plate
incub
hour
incub
fluoresc
intens
measur
fluoresc
plate
reader
excit
nm
emiss
nm
spectramax
paradigm
molecular
devic
ca
sampl
calcul
curv
fit
nonlinear
regress
use
graphpad
prism
graphpad
softwar
inc
ca
sera
neutral
titer
elicit
immun
prime
follow
first
boost
measur
mous
neutral
titer
elicit
second
boost
measur
four
time
averag
mous
except
sera
elicit
final
boost
immun
measur
three
time
mous
averag
previous
describ
protect
neutral
threshold
calcul
note
clinic
administr
palivizumab
synagi
mgkg
lead
patient
sera
level
trough
serum
concentr
provid
protect
infant
sever
diseas
protect
cotton
rat
rsv
infect
neutral
assay
describ
palivizumab
yield
competit
neutral
assay
probe
either
antigen
site
knock
ko
antigen
site
ii
ko
ad
sera
incub
one
hour
follow
addit
equal
volum
viru
incub
addit
hour
serarsv
frsv
mixtur
ad
cell
per
well
assay
plate
incub
hour
fluoresc
intens
well
read
describ
one
read
obtain
mous
sera
sampl
octet
instrument
use
measur
sera
recognit
antigen
site
ko
antigen
site
ii
ko
probe
assay
perform
tilt
black
plate
greiner
bioon
nc
agit
set
rpm
pb
supplement
bsa
well
volum
ko
probe
immobil
biosensor
tip
equilibr
pb
bsa
prior
measur
associ
sera
dilut
pb
supplement
bsa
associ
record
surfac
area
calcul
perform
use
chimera
coordin
pdb
entri
rsv
f
epitop
residu
motavizumab
delin
use
pisa
web
server
coordin
pdb
entri
respect
structur
figur
creat
use
program
chimera
rsv
f
trimer
coordin
pdb
entri
pref
structur
rsv
f
trimer
glycoprotein
divid
two
halv
membraneproxim
half
rsv
f
stalk
region
compris
domain
ii
primarili
structur
termin
ctermin
coil
coil
enter
membran
membranedist
half
rsv
f
head
region
compris
domain
iii
primarili
fig
two
halv
connect
long
twostrand
contain
one
strand
anoth
strand
rsv
f
head
contain
least
two
epitop
associ
neutral
antibodi
antigen
site
locat
apex
pref
trimer
recogn
potent
neutral
antibodi
includ
antigen
site
ii
locat
toward
middl
pref
trimer
fig
bind
site
antibodi
palivizumab
motavizumab
report
fold
less
potent
site
antibodi
antigen
site
iv
also
recogn
antibodi
lower
potenc
locat
rsv
f
stalk
region
epitop
quaternaryspecif
antibodi
straddl
head
stalk
region
sinc
rsv
f
stalk
compris
total
surfac
area
rsv
f
trimer
reason
express
headonli
region
rsv
f
might
help
focu
immun
respons
antigen
site
well
antigen
site
ii
therefor
design
variant
headonli
rsv
f
construct
use
three
differ
approach
fig
tabl
first
approach
domain
iii
express
simpl
monom
design
second
approach
domain
iii
express
tandemli
link
dimer
design
third
approach
trimer
domain
fuse
domain
iii
enabl
express
trimer
protein
resembl
nativ
prefus
rsv
f
head
design
topolog
rsv
f
remov
rsv
f
stalk
rsv
f
head
result
two
separ
polypeptid
within
head
protom
reconnect
polypeptid
make
singl
polypeptid
afford
opportun
permut
circularli
domain
topolog
link
either
fig
design
also
incorpor
disulfid
bond
well
caviti
fill
mutat
stabil
prefus
conform
numer
addit
mutat
includ
repack
protein
interior
addit
disulfid
bond
alter
surfac
mutat
replac
hydrophob
residu
hydrophil
residu
glycan
moreov
variou
length
glycin
rich
linker
use
link
two
polypeptid
domain
iii
connect
trimer
domain
final
signal
peptid
secret
cleavabl
histag
streptag
aid
purif
ad
construct
design
construct
codon
optim
express
human
cell
transfect
express
hek
cell
use
format
coupl
express
evalu
antigen
recognit
sever
potent
neutral
rsv
f
antibodi
target
antigen
site
three
monoclon
antibodi
mab
specif
site
use
readout
antibodi
addit
solubl
rsv
f
trimer
metast
spontan
convert
postfus
conform
bind
also
evalu
one
week
bind
evalu
two
five
week
respect
design
elisa
readout
higher
one
week
tabl
gaug
stabil
immunogen
recognit
also
evalu
one
hour
fifti
headonli
design
retain
major
antigen
one
hour
condit
parent
rsv
f
trimer
complet
lost
recognit
observ
substanti
decreas
bind
headonli
immunogen
tabl
reduc
list
immunogen
stabl
character
calcul
averag
antigen
score
compris
averag
maximum
elisa
read
bind
one
week
one
hour
well
bind
two
week
tabl
top
score
first
approach
construct
averag
antigen
score
expect
monom
top
score
second
approach
construct
averag
antigen
score
expect
dimer
top
score
third
approach
construct
expect
trimer
averag
antigen
score
design
circularli
permut
domain
iii
monom
fig
segment
residu
connect
short
gg
linker
ctermin
end
segment
result
differ
topolog
nativ
rsv
f
fig
addit
four
mutat
embodi
thirteen
addit
mutat
fig
introduc
includ
addit
disulfid
bond
well
alter
hydrophob
surfac
residu
hydrophil
glutamin
improv
solubl
design
tandemli
link
dimer
two
ident
domain
iii
monom
connect
gsg
linker
fig
monom
compris
residu
link
residu
short
gsg
linker
monom
also
contain
four
mutat
design
compris
circularli
permut
domain
iii
monom
residu
connect
residu
ggsgg
linker
connect
cterminu
ggsggsg
linker
bacteriophag
foldon
trimer
domain
fig
addit
mutat
three
hydrophob
surfac
residu
replac
hydrophil
residu
fig
design
also
circularli
permut
domain
iii
monom
residu
connect
residu
ggpg
linker
fig
howev
case
trimer
domain
comput
deriv
tripl
helic
coil
coil
refer
mtq
directli
connect
nterminu
domain
iii
polypeptid
without
linker
three
mutat
includ
stabil
four
top
score
headonli
immunogen
express
one
liter
cultur
cell
affin
purif
cleavag
purif
tag
size
exclus
chromatographi
use
character
oligomer
state
appropri
peak
pool
character
design
elut
three
peak
design
monom
chose
peak
correspond
monom
character
design
elut
primarili
singl
peak
correspond
dimer
trimer
trimer
respect
fig
assess
sizeexclus
purifi
immunogen
biolay
interferometri
recognit
site
antibodi
well
site
iidirect
antibodi
motavizumab
recogn
four
immunogen
nanomolar
affin
though
monom
dimer
display
slightli
lower
affin
trimer
immunogen
fig
tabl
although
antigen
site
iidirect
antibodi
motavizumab
recogn
trimer
dimer
nanomolar
affin
monom
trimer
display
micromolar
affin
unsurpris
contain
surfac
mutat
middl
motavizumab
epitop
immunogen
lowest
motavizumab
affin
addit
epitop
mutat
fig
moreov
four
top
score
design
chosen
recognit
site
antibodi
consider
given
recognit
site
iidirect
antibodi
assess
stabil
purifi
immunogen
quantifi
effect
high
temperatur
ph
extrem
osmolar
extrem
cycl
freezethaw
recognit
antibodi
tabl
four
immunogen
thermost
rsv
f
trimer
observ
robust
physic
extrem
outlier
loss
recognit
freezethaw
cycl
sensit
high
salt
remark
monom
still
viabl
heat
one
hour
show
loss
site
antigen
cycl
freezethaw
four
immunogen
examin
negativestain
electron
microscopi
em
without
antigenbind
fragment
fab
antibodi
motavizumab
follow
referencefre
classif
averag
probe
structur
fig
immunogen
monomer
structur
fig
bind
fab
readili
observ
fig
contrast
bind
motavizumab
alon
observ
less
particl
less
distinct
complex
fig
consist
micromolar
affin
motavizumab
furthermor
mix
motavizumab
one
bound
fab
observ
case
fig
tandemli
link
dimer
display
bilob
structur
lobe
close
contact
fig
bound
distal
end
lobe
suggest
domain
associ
membraneproxim
end
fig
expect
structur
prefus
rsv
f
motavizumab
fab
bound
differ
site
orient
rotat
approxim
fig
differ
orient
bound
fab
rel
also
observ
suggest
linkag
two
domain
quit
flexibl
unlik
immunogen
readili
bound
motavizumab
fab
simultan
fig
trimer
clearli
display
three
lobe
mani
imag
fig
howev
trimer
often
heterogen
quaternari
arrang
one
domain
appear
blurri
greater
separ
domain
might
expect
tendenc
form
oligom
complex
clear
stoichiometri
fab
frequent
appear
distinct
trimer
consist
heterogen
note
fig
similar
consist
low
micromolar
affin
motavizumab
trimer
observ
form
complex
complex
motavizumab
fig
likewis
mix
motavizumab
reveal
mostli
complex
like
repres
bound
alon
fig
trimer
display
dumbbel
shape
structur
two
differ
size
lobe
connect
thin
rod
fig
interpret
smaller
lobe
fray
nterminu
rodlik
coiledcoil
larger
lobe
trimer
rsv
f
head
addit
fab
result
trimer
starlik
structur
consist
bind
stoichiometri
propos
quaternari
arrang
fig
deviat
perfect
threefold
symmetri
indic
trimer
flexibl
though
extent
observ
bind
fab
motavizumab
also
result
trimer
starlik
structur
multipl
exampl
two
clearli
defin
fab
one
blurri
fab
bound
fig
result
suggest
either
configur
easili
view
two
dimens
one
protom
addit
flexibl
upon
motavizumab
fab
bind
similarli
complex
motavizumab
result
starlik
structur
fab
arm
clearli
present
though
often
blurri
fig
evalu
immunogen
four
top
score
headonli
immunogen
use
immun
group
mice
headonli
immunogen
adjuv
polyinosin
polycytidyl
acid
polyi
c
inject
intramuscularli
twice
interv
three
week
week
five
sera
significantli
higher
reciproc
neutral
titer
observ
mice
immun
gmt
respect
fig
titer
threefold
lower
observ
control
titer
statist
compar
induc
low
neutral
titer
unexpect
light
nanomolar
affin
observ
antigen
site
antibodi
tabl
fig
monom
rel
small
size
kda
may
hinder
immunogen
hydrophil
surfac
mutat
cover
approxim
surfac
area
fig
may
distract
antibodi
respons
neutral
epitop
trimer
quaternari
heterogen
observ
negativestain
em
suggest
unexpect
neoepitop
may
also
present
potenti
dilut
b
cell
respons
epitop
neutral
antibodi
immunogen
abl
induc
reason
rsvneutral
antibodi
investig
potenti
focu
antibodi
respons
headonli
antigen
site
heterolog
boost
mice
prime
twice
instanc
prime
interv
three
week
boost
interv
seven
week
boost
may
mimic
boost
individu
previous
expos
rsv
notabl
week
sera
show
headonli
boost
elicit
geometr
mean
titer
respect
statist
compar
mean
titer
rsv
f
control
fig
interestingli
revers
primeboost
headonli
prime
follow
boost
result
significantli
lower
respons
p
respect
fig
thu
dimer
trimer
appear
prime
well
full
length
appear
focu
boost
headdirect
neutral
respons
next
investig
whether
increas
rsvneutral
titer
heterolog
boost
direct
toward
antigen
site
ii
previous
develop
probe
knockout
ko
mutat
antigen
site
antigen
site
ii
use
sitespecif
ko
probe
quantifi
sitespecif
immun
respons
first
measur
rel
bind
affin
immun
sera
site
site
iiko
probe
homolog
primeboost
sera
signific
differ
observ
bind
three
probe
fig
entir
surpris
given
individu
knockout
mutat
antigen
site
ii
cover
small
percentag
surfac
area
respect
probe
contrast
site
probe
bound
significantli
less
boost
sera
p
respect
probe
fig
site
iiko
probe
also
bound
significantli
less
boost
sera
probe
p
bind
statist
compar
boost
sera
next
measur
competit
effect
antigen
site
site
ii
ko
probe
neutral
ad
sera
three
group
immun
mice
compet
sera
effici
expect
result
significantli
reduc
neutral
p
fig
howev
site
ko
site
ii
ko
probe
compet
much
less
effect
highlight
import
site
fig
group
antigen
site
ii
ko
probe
compet
strongli
antigen
site
ko
probe
p
respect
indic
antigen
site
domin
target
neutral
sera
group
howev
signific
differ
neutral
competit
antigen
site
site
ii
ko
probe
thu
regard
sitespecif
induc
respons
result
indic
rsvneutral
respons
boost
headonli
immunogen
inde
focus
headspecif
site
ii
especi
antigen
site
major
goal
rsvvaccin
develop
identifi
immunogen
boost
antibodi
respons
neutralizationsensit
epitop
set
preexist
immun
increas
serumneutr
activ
pregnant
women
would
help
increas
protect
respons
extend
period
maternallyacquir
protect
rsv
likewis
elderli
peopl
experienc
repeat
rsv
infect
throughout
life
still
modest
level
serumneutr
activ
boost
respons
neutralizationsensit
epitop
could
achiev
greater
threshold
level
protect
immun
therefor
took
structurebas
design
approach
produc
immunogen
focus
immun
recognit
apic
surfac
pref
trimer
remov
stalk
portion
rsv
f
trimer
glycoprotein
creat
rsv
f
headonli
immunogen
fifti
design
recogn
antibodi
metast
antigen
site
stabl
least
one
hour
temperatur
rapidli
inactiv
tabl
thermost
headonli
immunogen
includ
monom
dimer
trimer
four
monom
dimer
two
trimer
express
purifi
character
antigen
overal
stabil
structur
integr
immunogen
although
four
headonli
immunogen
display
nanomolar
affin
antigen
site
antibodi
physic
stabil
similar
exceed
one
immunogen
trimer
abl
elicit
rsvneutral
titer
mice
compar
elicit
fig
lower
overal
immunogen
headonli
immunogen
may
relat
increas
flexibl
protom
recent
found
reduct
interprotom
flexibl
pref
trimer
yield
higher
immunogen
two
immunogen
elicit
lowest
titer
rsv
neutral
geometr
mean
respect
low
micromolar
affin
antigen
site
iidirect
antibodi
motavizumab
wherea
induc
substanti
higher
titer
bound
motavizumab
nanomolar
affin
suggest
antigen
site
ii
may
potenti
play
role
overal
effect
headonli
immunogen
consist
neutral
competit
data
fig
small
size
extens
surfac
mutagenesi
monom
greater
structur
heterogen
surfac
mutat
trimer
rel
may
also
diminish
capabl
headonli
immunogen
contrast
mice
prime
boost
elicit
rsvneutral
respons
statist
compar
boost
importantli
focus
overal
antibodi
respons
antigen
site
ii
enhanc
mice
rel
boost
fig
despit
smaller
size
rel
dimer
natur
flexibl
may
facilit
dival
antibodi
bind
thu
enhanc
boost
result
demonstr
headonli
rsv
f
immunogen
boost
focu
enhanc
elicit
respons
antigen
site
associ
rsv
f
head
reduc
size
increas
thermost
headonli
immunogen
describ
may
also
advantag
term
express
manufactur
addit
mammalian
cell
cultur
small
immunogen
may
also
amen
less
expens
plant
bacterialbas
express
system
well
yeast
insect
cell
cultur
inde
full
length
rsv
f
protein
success
express
appl
tomato
insect
cell
furthermor
success
use
live
chimer
vector
sendai
human
parainfluenza
viru
type
replicationdefect
vector
adenoviru
modifi
vaccinia
ankara
express
rsv
f
protein
elicit
immun
respons
vectorimmun
anim
suggest
altern
deliveri
method
could
also
appli
headonli
rsv
f
immunogen
vaccin
set
design
even
smaller
rsv
f
headderiv
immunogen
less
extran
nonneutr
epitop
could
potenti
focu
rsv
f
immun
respons
still
howev
immunogen
design
could
complic
nonproxim
antigen
site
ii
retain
increas
cell
help
addit
univers
cell
epitop
peptid
requir
smallest
immunogen
although
observ
consist
correl
oligom
size
ie
monom
dimer
trimer
neutral
titer
immun
focus
increas
immunogen
oligomer
state
order
manner
might
also
expect
improv
immun
focus
sinc
would
provid
opportun
irrelev
epitop
mask
neighborneighbor
interact
addit
multival
target
epitop
could
lead
increas
b
cell
avid
antibodi
crosslink
result
increas
immunogen
epitop
therefor
addit
multimer
incorpor
nanoparticl
might
improv
immun
focus
overal
immunogen
headonli
rsv
f
immunogen
remain
seen
mani
headonli
immunogen
viabl
vaccin
candid
result
best
four
immunogen
nonetheless
alreadi
demonstr
abil
headonli
rsv
f
immunogen
boost
high
titer
previous
elicit
rsvneutral
respons
rsv
f
glycoprotein
togeth
result
indic
headonli
immunogen
particularli
suit
boost
rsv
fspecif
antibodi
respons
set
preexist
result
particular
signific
matern
immun
vaccin
protect
elderli
